SLDB insider trading
NasdaqGS HealthcareSolid Biosciences Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Solid Biosciences Inc.
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It also develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
Company website: www.solidbio.com
SLDB insider activity at a glance
FilingIQ has scored 305 insider transactions for SLDB since Jan 25, 2018. The most recent filing in our index is dated Apr 2, 2026.
Across the full history, 14 open-market purchases
and 106 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on SLDB insider trades is 56.8/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest SLDB Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading SLDB
13F funds holding SLDB
Frequently asked
- How many insider trades does FilingIQ track for SLDB?
- FilingIQ tracks 305 Form 4 insider transactions for SLDB (Solid Biosciences Inc.), covering filings from Jan 25, 2018 onwards. 10 of those were filed in the last 90 days.
- Are SLDB insiders net buyers or net sellers?
- Across the full Form 4 history for SLDB, 14 transactions (5%) were open-market purchases and 106 (35%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does SLDB insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is SLDB in?
- Solid Biosciences Inc. (SLDB) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $457.33M.
Methodology & sources
Every SLDB insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.